skip to main content

Title: Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation

Purpose: Recent research has enhanced our understanding of radiation injury at the molecular-cellular and tissue levels; significant strides have occurred in standardization of adverse event reporting in clinical trials. In response, the International Atomic Energy Agency, through its Division of Human Health and its section for Applied Radiation Biology and Radiotherapy, organized a consultation meeting in Atlanta (October 2, 2004) to discuss developments in radiobiology, normal tissue reactions, and adverse event reporting. Methods and Materials: Representatives from cooperative groups of African Radiation Oncology Group, Curriculo Radioterapeutica Ibero Latino Americana, European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada Clinical Trials Group, Radiation Therapy Oncology Group, and Trans-Tasman Radiation Oncology Group held the meeting discussion. Results: Representatives of major radiotherapy groups/organizations and prominent leaders in radiotherapy discussed current understanding of normal tissue radiobiologic effects, the design and implementation of future clinical and translational projects for normal tissue injury, and the standardization of adverse-event reporting worldwide. Conclusions: The consensus was to adopt NCI comprehensive adverse event reporting terminology and grading system (CTCAE v3.0) as the new standard for all cooperative group trials. Future plans included the implementation of coordinated research projects focusing on normal tissue biomarkers and datamore » collection methods.« less
Authors:
 [1] ;  [2] ;  [3] ;  [4] ;  [5] ;  [6] ;  [7] ;  [8] ;  [9] ;  [10]
  1. Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY (United States). E-mail: Yuhchyau_chen@urmc.rochester.edu
  2. Division of Radiation Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL (United States)
  3. Radiation Oncology Sciences Program, National Cancer Institute, Bethesda, MD (United States)
  4. Radiation Oncology at Thomas Jefferson University Hospital, Philadelphia, PA, and Radiation Therapy Oncology Group (United States)
  5. Centre Hospitalier Universitaire, Vaudois, Lausanne (Switzerland) and European Organization for Research and Treatment of Cancer, Brussels (Belgium)
  6. British Columbia Cancer Agency, Vancouver (Canada) and National Cancer Institute of Canada Clinical Trials Group, Toronto, Ontario (Canada)
  7. Department of Radiation Oncology, Newcastle Mater Hospital, and Trans-Tasman Radiation Oncology Group, Newcastle, New South Wales (Australia)
  8. National Institut of Oncology, Rabat (Morocco) and African Radiation Oncology Group, Cape Town (South Africa)
  9. Hospital do Cancer-A.C. Camargo, Sao Paulo (Brazil) and Curriculo Radioterapeutica Ibero Latino Americana, Lima (Peru)
  10. Applied Radiation Biology and Radiotherapy Section, International Atomic Energy Agency, Vienna (Austria)
Publication Date:
OSTI Identifier:
20793430
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 64; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2005.10.014; PII: S0360-3016(05)02818-X; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOLOGICAL MARKERS; CLINICAL TRIALS; IAEA; IMPLEMENTATION; MEETINGS; NEOPLASMS; PUBLIC HEALTH; RADIATION INJURIES; RADIOBIOLOGY; RADIOTHERAPY; TOXICITY